The introduction of Afrezza (insulin human) inhalation powder represented a meaningful shift in diabetes care, offering adults with type 1 or type 2 diabetes a needle-free alternative for prandial insulin therapy. By delivering rapid-acting insulin directly to the lungs via a breath-powered inhaler, Afrezza mimics the natural insulin peak that occurs after eating, with an onset that often outpaces injectable options. For patients who struggle with injections or desire faster glucose control, this device can be life-changing. However, the pulmonary route introduces a critical variable: the respiratory system is not merely a passive gateway but an active, metabolically complex interface. Because Afrezza deposits insulin crystals into the bronchial tree and alveoli, the lungs become a direct site of drug exposure. This makes regular lung function monitoring not just a precaution but a mandatory component of safe, long-term therapy. This article provides an expanded look at why lung function tests are essential for Afrezza users, covering mechanisms of pulmonary impact, clinical evidence, monitoring protocols, patient self-management, and the collaborative care framework needed to balance glycemic control with respiratory safety.

Why Lung Function Monitoring Matters with Afrezza

Afrezza received FDA approval in 2014 for both type 1 and type 2 diabetes, accompanied by a boxed warning about the risk of acute bronchospasm in patients with chronic lung disease such as asthma or COPD. This warning is not merely regulatory boilerplate—it reflects a real risk that has been documented in clinical trials and post-marketing surveillance. Even in individuals with no baseline respiratory illness, inhaled insulin can cause measurable changes in pulmonary mechanics. The direct contact of insulin crystals with bronchial epithelium and alveolar surfaces may trigger inflammatory or irritant responses, potentially leading to a decline in forced expiratory volume in one second (FEV₁). Understanding these mechanisms helps clinicians and patients appreciate why routine monitoring is non-negotiable.

The Unique Pulmonary Delivery System

Afrezza uses a dry powder formulation containing insulin crystals adsorbed onto fumaryl diketopiperazine (FDKP) carrier particles. When inhaled, the powder dissolves rapidly at the neutral pH of the alveolar surface, releasing insulin for absorption. This design enables rapid systemic uptake, with peak insulin levels reached in about 12-15 minutes—faster than any injectable rapid-acting analog. However, the same properties that enable fast absorption also create potential for local respiratory effects. The alveolar epithelium is highly permeable, allowing efficient drug transfer, but it is also vulnerable to irritation from repeated exposure to foreign particles. Animal studies and human histopathologic samples suggest that repeated deposition of insulin crystals may produce subclinical inflammation and mild, reversible thickening of the alveolar-capillary membrane. Additionally, the inhalation maneuver itself can provoke bronchoconstriction in susceptible individuals. These factors combine to create a risk profile that demands objective spirometric surveillance before and during therapy.

Understanding the Boxed Warning and Contraindications

Afrezza is explicitly contraindicated in patients with asthma or COPD. The boxed warning also notes that acute bronchospasm has been reported in patients without prior lung disease, particularly with the first dose. For this reason, the initial administration should occur under medical supervision, with spirometry available. Clinicians must confirm the absence of active lung disease before prescribing and educate patients about warning signs such as wheezing, chest tightness, or dyspnea. The boxed warning is a reminder that the pulmonary route is not appropriate for everyone; careful patient selection is the first line of defense against serious adverse events.

How Inhaled Insulin Affects the Lungs

The lungs are metabolically active organs with their own immune surveillance systems. When insulin crystals and FDKP particles are deposited repeatedly, the respiratory tract may respond in several ways. Understanding these responses helps clarify why lung function tests are sensitive enough to detect early changes before symptoms develop.

Mechanisms of Pulmonary Impact

Three primary mechanisms contribute to Afrezza-related pulmonary changes. First, direct irritation of the bronchial epithelium by the dry powder can trigger cough and transient bronchoconstriction, especially in individuals with heightened airway sensitivity. Second, the FDKP carrier may activate innate immune pathways, leading to recruitment of macrophages and neutrophils to the alveolar space. Studies show that this inflammatory response is usually mild and self-limited, but in some individuals it can become persistent, driving a gradual decline in FEV₁. Third, the insulin molecule itself may have local effects on airway smooth muscle and vascular tone. While insulin is generally considered anti-inflammatory, its effects in the lung are not fully characterized. The net result is that a small percentage of users experience a measurable decline in lung function, which is why monitoring is essential.

Acute vs. Chronic Changes

Acute changes following Afrezza inhalation include cough (reported in about 30% of users), which often diminishes with continued use as the airways adapt. More concerning are acute bronchospasm, wheezing, or chest tightness that occur within minutes of dosing. These events can happen even in patients with no prior history of lung disease, though they are more common in those with undiagnosed airway hyperreactivity. Chronic changes refer to a slow, progressive decline in FEV₁ observed over months to years of use. Clinical trial data show an average decline of less than 50 mL per year, which typically plateaus after 12 weeks. However, the long-term trajectory beyond two years is not fully characterized, prompting some experts to recommend more frequent monitoring for patients who plan to use Afrezza for extended periods.

The Role of Lung Function Tests

Standard pulmonary function tests (PFTs) provide objective, reproducible measures of lung health. For Afrezza users, these tests serve dual roles: baseline risk assessment before starting therapy and longitudinal safety monitoring during treatment. Choosing the right tests and interpreting them correctly is key to effective surveillance.

Spirometry: The Gold Standard for Monitoring

Spirometry measures FEV₁, forced vital capacity (FVC), and the FEV₁/FVC ratio. FEV₁ is the most sensitive endpoint for detecting Afrezza-related changes because it reflects airflow in the large and small airways. A decline of 20% or more from baseline, confirmed on repeat testing, warrants discontinuation of the drug and referral to a pulmonologist. Testing should follow American Thoracic Society (ATS) and European Respiratory Society (ERS) guidelines for reproducibility, and patients should avoid short-acting bronchodilators for at least four hours prior if clinically safe, to avoid masking bronchospasm. Baseline spirometry is mandatory before starting Afrezza, repeated at six months, and at least annually thereafter. For patients who smoke, have a history of respiratory symptoms, or show a decline of more than 15% from baseline, more frequent testing every three to six months is advisable. Spirometry should be performed by trained personnel in a setting that can handle acute bronchospasm, especially during the first dosing visit. The ATS technical standards for spirometry provide detailed guidance on quality assurance and interpretation.

Peak Expiratory Flow for Daily Self-Assessment

Peak expiratory flow (PEF) monitors are inexpensive, portable devices that measure the maximum speed of exhalation. While less sensitive than FEV₁, PEF is useful for daily self-monitoring, especially in patients who develop variable symptoms or who are at higher risk for bronchospasm. A drop of more than 20% from baseline or diurnal variation exceeding 20% should prompt a call to the healthcare provider. Training patients to maintain a peak flow diary fosters engagement in respiratory health and can catch early declines between clinic visits. Patients should be taught to perform three blows each morning before taking their Afrezza dose and to record the highest value. Over time, this gives a personalized picture of airway stability. Combining PEF monitoring with a symptom diary allows patients to recognize patterns and report changes promptly. For those using a rescue inhaler such as albuterol, PEF can also help assess the effectiveness of bronchodilator therapy.

Advanced Tests: DLCO and Impulse Oscillometry

Diffusion capacity for carbon monoxide (DLCO) evaluates gas transfer across the alveolar-capillary membrane. While not routinely required, DLCO may be ordered if spirometry is normal but the patient reports unexplained dyspnea, or if interstitial lung disease is suspected. Insulin itself typically does not affect DLCO, but the FDKP carrier has been scrutinized for potential inflammatory effects on the alveolar membrane. Body plethysmography measures total lung capacity and residual volume but is rarely necessary for routine Afrezza surveillance. Impulse oscillometry (IOS), which assesses airway resistance at various frequencies, is a promising tool for early detection of small airways dysfunction and may become more widely used as evidence accumulates. However, it is not yet incorporated into clinical guidelines for Afrezza monitoring, so its role remains primarily in research and specialized pulmonary practice.

Reviewing the Clinical Evidence

The safety profile of Afrezza with respect to lung function is supported by data from phase 3 clinical trials, extension studies, and post-marketing surveillance. Understanding what these studies show—and what they do not—is important for both clinicians and patients.

Findings from Phase 3 Trials and Post-Market Data

In the pivotal trials, Afrezza users showed a small but statistically significant decline in FEV₁ compared with injectable insulin comparators. The average decline was modest—typically less than 50 mL per year—and often plateaued after 12 weeks of therapy. This plateau has led some experts to suggest an adaptive mechanism, while others caution that subclinical inflammation may progress slowly over years. Individual variability is significant; some patients experience a rapid decline or acute bronchospasm after the first dose, requiring immediate intervention. Post-marketing analysis of adverse event reports found that bronchospasm accounted for a disproportionate number of serious pulmonary events, leading to the drug's contraindication in active lung disease. Even patients with no prior respiratory history can have a first-dose reaction, reinforcing the need for supervised initial dosing. The FDA continues to monitor pulmonary adverse events through its Afrezza safety information page, which is updated as new data emerge.

Individual Variability and Risk Factors

Not everyone who uses Afrezza experiences a decline in lung function. Some patients maintain stable FEV₁ over years of use, while others show gradual decreases. Identifying who is at higher risk is an active area of research. Known risk factors include smoking (even former smoking), a history of recurrent bronchitis, mild asthma in remission, and elevated baseline airway responsiveness. Diabetes itself contributes to reduced lung function through mechanisms such as glycation of pulmonary connective tissue and autonomic neuropathy. Adding a potential pulmonary insult from inhaled insulin may accelerate these changes in some patients. Genetic polymorphisms affecting airway inflammation, mucus production, or immune response may also play a role, but testing for these is not yet part of routine clinical practice. For now, the best approach is to monitor all patients uniformly and adjust the testing interval based on individual trends.

Monitoring Protocols and Guidelines

The prescribing information for Afrezza is explicit: "Spirometry should be performed prior to initiating therapy, after 6 months of therapy, and annually thereafter." This recommendation is echoed by the American Diabetes Association Standards of Medical Care and the Endocrine Society. For patients with a history of asthma or COPD, Afrezza is contraindicated, and clinicians should confirm the absence of active lung disease before writing the first prescription. Real-world implementation, however, requires more nuance. The following framework outlines a practical monitoring protocol.

  • Pre-initiation baseline: Full spirometry (FEV₁, FVC, FEV₁/FVC) within 30 days before starting Afrezza. Confirm no active lung disease.
  • First dose supervision: Administer first dose in a setting where spirometry is available and acute bronchospasm can be managed. Measure FEV₁ 15 and 30 minutes post-dose.
  • Follow-up at 3–6 months: Repeat spirometry to capture early changes. More frequent testing if the patient smokes, has a history of respiratory symptoms, or shows a decline of more than 10% from baseline.
  • Annual testing thereafter: At a minimum, annual spirometry for all Afrezza users. Consider semiannual testing for patients with risk factors.

This schedule is a starting point; some clinicians opt for more frequent testing during the first year, especially for patients who are new to inhaled therapy or who have borderline lung function at baseline. Every clinic should have a clear protocol for when to repeat testing and when to refer to a pulmonologist.

Step-by-Step Management of FEV₁ Decline

When a decline in FEV₁ is detected, a systematic approach helps determine causality and appropriate action:

  1. Confirm the decline: Repeat spirometry within one to two weeks to verify a persistent trend. Acute factors such as recent infection, poor effort, or improper technique can cause a false-positive result.
  2. Assess for symptoms and confounders: Inquire about new cough, wheeze, smoking status, inhaler technique, recent infections, and exposure to respiratory irritants.
  3. Consider a drug holiday: Temporarily discontinue Afrezza while monitoring recovery of lung function. A return to baseline after discontinuation supports a causal relationship.
  4. Determine causality: If FEV₁ returns to baseline after a drug holiday, the link to Afrezza is likely, and alternative insulin therapy should be pursued. If FEV₁ remains low despite discontinuation, evaluate for COPD exacerbation, infection, thoracic restriction, or other pulmonary diseases.
  5. Collaborate with pulmonology: Early referral to a pulmonologist is appropriate when the decline is greater than 20%, when symptoms are severe, or when there is diagnostic uncertainty.

It is important to note that a temporary decline in FEV₁ does not always mean permanent damage. In many cases, lung function stabilizes or returns to baseline after dose adjustment or drug holiday. The goal of monitoring is to catch changes early so that intervention can preserve respiratory health without unnecessarily limiting diabetes treatment options.

When to Discontinue Afrezza

Discontinuation should be considered when FEV₁ declines by 20% or more from baseline and does not recover after a drug holiday, or when acute bronchospasm occurs after any dose. Patients who experience severe wheezing, chest tightness, or dyspnea requiring bronchodilator therapy should not resume Afrezza. In cases where FEV₁ declines between 15% and 20% and symptoms are absent or mild, shared decision-making with the patient can weigh the benefits of Afrezza against the potential risk. Some patients may choose to continue with more frequent monitoring, while others may prefer to switch to injectable insulin to eliminate pulmonary concerns altogether.

Building a Patient Self-Management Strategy

Empowering patients with knowledge about their lung health is key to adherence and safety. Patients who understand what their spirometry numbers mean, how to use their inhaler correctly, and when to seek help are more likely to remain on therapy safely. The following components form the foundation of a strong self-management strategy.

Recognizing Warning Signs

Patients should be instructed to report any new or worsening cough, wheezing, chest tightness, or shortness of breath—especially if these symptoms occur within minutes to hours after taking a dose. They should also be told that a mild cough immediately after inhalation is common and often improves with continued use, but a cough that worsens over time or is accompanied by other symptoms should not be ignored. Written materials listing warning signs and contact numbers should be provided at the initial visit and reviewed at follow-up appointments. An easy-to-remember summary: "If your breathing changes after your dose, stop and call your care team."

Proper Inhaler Technique

Correct inhaler technique minimizes upper-airway deposition and maximizes alveolar delivery, which may reduce local irritation and improve insulin absorption. Patients should be observed using the device during the initial visit and at follow-up appointments. Common errors include exhaling into the device, failing to hold the breath for five seconds after inhalation, and blocking the air vents with the teeth or lips. The steps for correct use are simple but must be reinforced:

  1. Insert a single cartridge into the inhaler.
  2. Exhale fully away from the device.
  3. Seal the lips around the mouthpiece, keeping the air vents clear.
  4. Inhale deeply and steadily through the mouth.
  5. Hold the breath for five seconds, then exhale normally.
  6. Discard the cartridge after use.

Repetition and coaching at each visit help maintain technique. Patients who struggle with coordination may benefit from a demonstration video or a return demonstration during the office visit. In some cases, a referral to a diabetes educator or respiratory therapist can improve technique and confidence.

Smoking Cessation and Lifestyle Factors

Smoking is an absolute contraindication for Afrezza users. Cigarette smoke irritates airways and accelerates the decline in FEV₁, compounding any drug-related effect. Smoking cessation counseling and pharmacotherapy—such as nicotine replacement therapy, varenicline, or bupropion—should be offered to all patients who use Afrezza and smoke. The same applies to e-cigarettes and vaping products; the vapor's impact on inhaled insulin absorption is unknown, but the potential for harm outweighs any theoretical benefit. Occupational exposures to dust, fumes, or chemical irritants should also be discussed, and patients should be advised to use appropriate respiratory protection when necessary. Maintaining good overall health through exercise, adequate hydration, and management of comorbid conditions such as allergies or sinusitis can help keep the respiratory system resilient.

Home Action Plans for Lung Health

A simple symptom diary combined with home peak flow monitoring can help patients become active partners in their care. An example action plan based on peak flow readings and symptoms provides clear guidance:

  • Green zone (FEV₁ > 90% of personal best, no symptoms): Continue Afrezza as prescribed. No changes needed.
  • Yellow zone (FEV₁ 80–90% of personal best, or mild cough/wheeze): Contact healthcare provider within 24–48 hours. Do not adjust insulin without guidance. Consider repeating spirometry in the office.
  • Red zone (FEV₁ < 80% of personal best, or moderate-to-severe dyspnea, wheeze at rest, or chest tightness): Discontinue Afrezza immediately. Seek medical attention promptly. If a rescue inhaler has been prescribed, use it as directed.

Patients should also know that if they experience acute bronchospasm after any dose, they should not take the next dose and should carry a rescue inhaler if prescribed. The first dose should always be administered under medical supervision, as even patients with no known lung disease can have a severe reaction. An action plan gives patients a clear pathway from self-monitoring to professional evaluation, reducing the risk of delay in recognizing a serious problem.

Collaboration Between Specialists

Managing a patient on Afrezza is a team effort. The endocrinologist or primary care provider typically prescribes and monitors insulin therapy and glycemic control. The pulmonologist provides expertise in interpreting lung function tests, managing bronchospasm, and evaluating new respiratory symptoms. When a decline in FEV₁ is detected, communication between these specialists is critical. A multidisciplinary approach ensures that diabetes control is not compromised while respiratory safety is protected. Shared electronic health records and direct communication (phone call, secure messaging, or joint clinic visit) can prevent delays in decision-making. For patients with complex medical histories—such as those with diabetes and mild asthma or obesity hypoventilation syndrome—a baseline consultation with a pulmonologist before starting Afrezza may be prudent. In all cases, the goal is to balance the proven benefits of Afrezza for glycemic control with the need to protect long-term respiratory health.

The CDC offers general guidance on lung health for people with diabetes, which can be shared with patients as a starting point for understanding the intersection of diabetes and respiratory function. Combining this with drug-specific education from the official Afrezza patient site (MannKind) gives patients a well-rounded perspective on their care.

Final Thoughts on Safe Use of Afrezza

Afrezza offers a valuable alternative to injectable prandial insulin, particularly for patients who are needle-averse or who need the fastest possible insulin onset for postprandial glucose control. However, the pulmonary route demands respect. Regular lung function tests—primarily spirometry—provide an objective, reproducible measure of respiratory health that can detect adverse effects before they become symptomatic or irreversible. The current evidence base supports baseline testing before initiation, a follow-up test at three to six months, and annual testing thereafter, with enhanced frequency for those at higher risk. By adhering to these monitoring schedules and educating patients about signs of pulmonary trouble, clinicians can help ensure that the benefits of Afrezza are not overshadowed by preventable harm. For patients, a proactive stance on lung health—non-smoking, proper inhaler technique, symptom awareness, and adherence to testing—is the foundation of safe, effective therapy. When both the prescriber and the patient commit to this partnership, Afrezza can remain a successful tool in the diabetes management arsenal for years to come.